Post-earnings recap
Reported
Mon, Aug 9, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report showed a narrower-than-expected loss per share, which contributed to a slight increase in stock price. Investors may be encouraged by management's focus on R&D and their commitment to future growth, despite the lack of revenue figures and guidance. The stock's positive reaction suggests that the market is cautiously optimistic about the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | +0.40% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their product pipeline. They acknowledged the challenges but emphasized their commitment to innovation.
Management highlighted ongoing research and development efforts.
They expressed confidence in their pipeline despite current losses.